Roles of fibroblast growth factor 19 in obesity and diabetes mellitus / 国际生物医学工程杂志
International Journal of Biomedical Engineering
; (6): 491-495,512, 2021.
Article
de Zh
| WPRIM
| ID: wpr-929939
Bibliothèque responsable:
WPRO
ABSTRACT
Fibroblast growth factor 19 (FGF19) is an endocrine hormone and it's primarily regulated by bile acids. FGF19 helps to reduce body weight, a variety of weight loss mechanism are achieved by increasing the level of FGF19. FGF19 can reverse mitochondrial dysfunction caused by obesity. The main pathogenesis of diabetes is insulin resistance and islet β cell defects, which can cause microangiopathy and cardiovascular diseases. FGF19 can fundamentally protect the function of islet β cells, improve insulin resistance, increase insulin sensitivity, and achieve the purpose of reducing blood glucose by insulin-independent manner. Diabetic patients have different degrees of complications. FGF19 can protect the diabetic cardiomyocytes by improving the energy metabolism of diabetic cardiomyocytes. It may play a protective role in the development of diabetic retinopathy and diabetic nephropathy. The results of this review paper show that FGF19 plays an important role in the treatment of obesity, diabetes and its complications, and regulating FGF19 is expected to become a new strategy for the treatment of obesity and diabetes.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
International Journal of Biomedical Engineering
Année:
2021
Type:
Article